[
    [
        {
            "time": "2023-10-10",
            "original_text": "基因细胞治疗CDMO：新兴赛道蓬勃发",
            "features": {
                "keywords": [
                    "基因",
                    "细胞",
                    "治疗",
                    "CDMO",
                    "新兴",
                    "赛道",
                    "蓬勃"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "基因细胞治疗CDMO：新兴赛道蓬勃发",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "【权益变动】康龙化成(03759.HK)被FMRLLC减持5.96万股 减持股",
            "features": {
                "keywords": [
                    "康龙化成",
                    "减持",
                    "FMRLLC",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【权益变动】康龙化成(03759.HK)被FMRLLC减持5.96万股 减持股",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "康龙化成(03759)股东已累计减持1676.85万股 减持股份",
            "features": {
                "keywords": [
                    "康龙化成",
                    "股东",
                    "累计减持",
                    "股份"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康龙化成(03759)股东已累计减持1676.85万股 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "康龙化成(03759.HK)：减持期过半 君联闻达及君联茂林合计减持2.11%股份 减持股份",
            "features": {
                "keywords": [
                    "康龙化成",
                    "减持期",
                    "君联闻达",
                    "君联茂林",
                    "股份"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康龙化成(03759.HK)：减持期过半 君联闻达及君联茂林合计减持2.11%股份 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "康龙化成今日大宗交易成交30万股，成交价210.33元折价1.4%",
            "features": {
                "keywords": [
                    "康龙化成",
                    "大宗交易",
                    "成交",
                    "折价"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康龙化成今日大宗交易成交30万股，成交价210.33元折价1.4%",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "医药股在香港集体爆发 行业多重利好催化审评审批效率提速",
            "features": {
                "keywords": [
                    "医药股",
                    "香港",
                    "爆发",
                    "利好",
                    "审评审批",
                    "效率"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药股在香港集体爆发 行业多重利好催化审评审批效率提速",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "中泰证券：药品审评审批“速”“质”提升，全面利好医药行业发展",
            "features": {
                "keywords": [
                    "中泰证券",
                    "药品",
                    "审评审批",
                    "提升",
                    "医药行业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰证券：药品审评审批“速”“质”提升，全面利好医药行业发展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "CXO行业成医药基金宠儿",
            "features": {
                "keywords": [
                    "CXO",
                    "医药基金",
                    "宠儿"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "CXO行业成医药基金宠儿",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]